CVS Health is a stock, not an exchange-traded fund, so the central target is built from analyst price targets. S&P Global data collected across roughly 27 analysts places the average 12-month price target near $115.48, which rounds to a clean $115. The range is unusually wide — approximately $103 on the low end to $145 on the high end — which underscores how differently analysts frame the company's recovery.
Recent individual calls illustrate the spread. Bank of America reiterated a Buy with a $110 target in mid-October 2026, Leerink Partners lowered its target to $112 (from $119) while keeping an Outperform rating, RBC Capital stood at $113, and Bernstein moved to $112. On the more constructive side, UBS and JPMorgan each carried $118 targets, while Wells Fargo held a high-profile $123 target. At the cautious end, HSBC maintained a Hold with a $103 target, and Cantor Fitzgerald reiterated a Neutral stance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The consensus skews decisively positive — often described as Strong Buy or Moderate Buy — with a large majority of analysts in the bullish camp and only a handful of holds. There are essentially no sell ratings, yet the gap between the lowest and highest targets shows that analysts disagree on the pace and durability of margin recovery rather than on the company's direction.
The stock closed near $90.25 in late October 2026, inside a 52-week range of roughly $69.51 to $110.68. Reaching $115 requires a gain of about 27%, a substantial move that would take the shares above their prior 52-week high. It would not be a record-breaking run, but it would require sustained earnings delivery and a meaningful re-rating of sentiment.
The path would likely run through continued improvement in the Health Care Benefits segment, where Aetna's medical benefit ratio (the share of premiums spent on care) has been normalizing, and through steadier contribution from the pharmacy and Caremark PBM businesses. With a market capitalization near $115 billion, a trailing P/E (price-to-earnings ratio) in the mid-20s, and a dividend yield near 3%, the stock remains a value-and-income story that bulls argue has yet to fully price in earnings recovery.
The most important support is earnings momentum. CVS has beaten estimates in recent quarters — one report showed EPS (earnings per share) of $2.58 against a roughly $1.87 consensus — and management has raised full-year guidance multiple times. Full-year 2026 guidance sits around $7.90 to $8.10 per share, with analysts near the middle of that range.
Beyond the numbers, improving Medicare Advantage star ratings and the company's redesigned MA benefits give analysts visibility into durable margin expansion. A broader rotation into healthcare stocks, strong free cash flow, and cost-control progress across the insurance and pharmacy segments are also cited as tailwinds. If quarterly results continue to beat and guidance keeps rising, analysts could lift targets further, narrowing the distance to $115.
The clearest obstacle is the managed-care underwriting cycle. Goldman Sachs and others have described the current downturn as among the most significant in more than 15 years, and a slower-than-expected recovery in Medicaid and ACA exchange plans could keep medical costs elevated. Regulatory risk also looms — proposed changes to PBM practices, pharmacy reimbursement, and Affordable Care Act subsidies could pressure revenue and margins.
Valuation is a secondary concern. Even after the recovery, CVS trades at a premium to some healthcare peers, and any guidance cut or renewed spike in medical costs could compress the multiple. Persistent competition from rivals such as Amazon and Walmart in retail pharmacy, along with a leveraged balance sheet, adds further downside risk that could keep the shares below even the lowest analyst targets.
Technically, the stock is in a longer-term recovery after a deep drawdown, but it remains below the $110.68 52-week high, which now acts as the nearest major resistance level ahead of the $115 target. The $100 psychological level is the next obvious hurdle. On the downside, support has repeatedly formed in the $86 to $90 zone, with the 52-week low near $69.51 representing a deeper floor. A sustained move above the prior high would signal a structural breakout, while repeated failures near $100 could keep the range intact.
Analyst price targets generally reflect a forward research horizon of about 12 months, though firms vary, and the company's own multi-year margin story extends beyond that window. The next key event is CVS Health's quarterly earnings, scheduled for early November 2026, where investors will watch medical benefit ratio trends, Medicare Advantage enrollment, full-year guidance, and any commentary on 2027. Beyond earnings, monitor analyst target revisions, ACA subsidy and PBM regulatory developments, healthcare sector rotation, and the stock's behavior around the $100 and $110.68 levels.
I often rely on Tickeron's AI Daily Buy/Sell Signals to stay on top of shifting trends in names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from market conditions and technical behavior. It serves as a practical complement to fundamental work, helping surface opportunities and track evolving positions without replacing core research.
The $115 central target — the rounded average of roughly 27 analyst price targets — sits about 27% above the recent price near $90.25. It is achievable only if the company's earnings recovery, led by Aetna's margin normalization, continues at its current pace and if regulatory and underwriting headwinds do not resurface. The wide $103-to-$145 analyst range signals real uncertainty, and the fact that the shares trade below even the lowest named target shows investors remain more cautious than analysts. The next earnings report, margin trends, and any analyst revisions will be the clearest indicators of whether the gap toward $115 begins to close. From what I see, this remains a story worth following closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for CVS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
The Momentum Indicator moved below the 0 level on November 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 54 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 32 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
CVS moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CVS moved below the 200-day moving average on November 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVS's RSI Oscillator exited the oversold zone, 21 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 222 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 168 of 252 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.346) is slightly lower than the industry average of (3.520). P/E Ratio (21.950) is within average values for comparable stocks, (126.353). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.032) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an integrated pharmacy health care provider
Industry ManagedHealthCare